27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) has collaborated with Vinbiocare to establish a manufacturing facility in Vietnam for its investigational COVID-19 vaccines for sale and use within Vietnam.
- Under the terms of the arrangement, Vinbiocare will, with consultation from Arcturus, build out a manufacturing facility in Vietnam.
- Arcturus will provide Vinbiocare access to proprietary technologies and processes to manufacture Arcturus' investigational COVID-19 vaccines.
- Arcturus will provide Vinbiocare with an exclusive license to manufacture the vaccines solely for distribution in Vietnam.
- Technology transfer is underway.
- Vinbiocare will make an upfront payment of $40 million and be responsible for costs associated with the technology transfer.
- Vinbiocare will also pay for mRNA drug substances supplied by Arcturus and royalties on vaccines produced at the facility.
- Arcturus COVID-19 vaccine candidate utilizes self-transcribing and replicating (STARR) mRNA technology and is delivered with Arcturus's lipid-mediated delivery system called LUNAR delivery system.
- Price Action: ARCT shares are up 4.92% at $32.85 during the premarket session on the last check Monday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!